Profound Medical

For the millions of men currently living with prostate cancer, and the thousands more who are diagnosed with it every year, current treatment options often mean having to make difficult choices based on potential side effects that can significantly impact quality of life. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate cancerous prostate tissue with precision, while actively protecting critical anatomy from potential side effects; a tomorrow where patients have access to a safe, fast and effective treatment option, so they can quickly return to their daily lives.

Established in 2008, Profound Medical is commercializing a novel technology, TULSA-PRO™, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO™ is CE Marked and Profound is sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of this innovative technology.

Type
Public
HQ
Mississauga, CA
Founded
2008
Size (employees)
784 (est)
Profound Medical was founded in 2008 and is headquartered in Mississauga, CA

Profound Medical Office Locations

Profound Medical has offices in Mississauga and Hamburg
Mississauga, CA (HQ)
6 2400 Skymark Ave
Hamburg, DE
9 Kehrwieder

Profound Medical Data and Metrics

Profound Medical Financial Metrics

CAD

Market capitalization (21-Jul-2017)

55.3 m

Closing share price (21-Jul-2017)

1
Profound Medical's current market capitalization is $55.3 m.

Profound Medical Market Value History

Traffic Overview of Profound Medical

Profound Medical Online and Social Media Presence

Profound Medical News and Updates

Redefining The Future of Medicine: 72 Medical Device Startups Advancing Treatment And Prevention

Medical device funding is on track to reach $3.5B in 2016, a slight increase over last year’s dollar total. Since 2012, most funding to medical device startups has occurred in the United States, with NEA leading venture capital activity and Johnson & … Continued

BRIEF-Profound Medical says co, Royal Philips jointly sold TULSA-PRO system in UK

* Co, royal philips jointly sold tulsa-pro system in united kingdom to ucl and uclh Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Profound Medical Company Life and Culture

You may also be interested in